Venetoclax in Lymphoid Malignancies: New Insights, More to Learn

Rachel Thijssen; Andrew W Roberts

doi:10.1016/j.ccell.2019.09.008

Venetoclax in Lymphoid Malignancies: New Insights, More to Learn

Cancer Cell. 2019 Oct 14;36(4):341-343. doi: 10.1016/j.ccell.2019.09.008.

Authors

Rachel Thijssen¹, Andrew W Roberts²

Affiliations

¹ The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, VIC 3052, Australia.
² The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, VIC 3052, Australia; Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, 305 Grattan Street, Melbourne, VIC 3000, Australia; Department of Medical Biology and Centre for Cancer Research, University of Melbourne, Melbourne, VIC 3000, Australia; Victorian Comprehensive Cancer Centre, 305 Grattan Street, Melbourne, VIC 3000, Australia. Electronic address: roberts@wehi.edu.au.

PMID: 31614111
DOI: 10.1016/j.ccell.2019.09.008

Abstract

In this issue of Cancer Cell, Guièza et al. describe that overexpression of the pro-survival protein MCL1 and cellular energy metabolic reprogramming can contribute to resistance to the BCL2 inhibitor venetoclax in patients with chronic lymphocytic leukemia. This adds a new dimension to understanding of secondary clinical resistance to venetoclax.

Publication types

Comment

MeSH terms

Antineoplastic Agents*
Bridged Bicyclo Compounds, Heterocyclic
Humans
Leukemia, Lymphocytic, Chronic, B-Cell*
Proto-Oncogene Proteins c-bcl-2
Sulfonamides

Substances

Antineoplastic Agents
Bridged Bicyclo Compounds, Heterocyclic
Proto-Oncogene Proteins c-bcl-2
Sulfonamides
venetoclax